NICE greenlights RoActemra, snubs Afinitor

The U.K.'s cost-effectiveness watchdog changed its mind to recommend Roche's arthritis drug RoActemra for use by the National Health Service, but it rejected the use of Novartis' Afinitor in patients with kidney cancer. Report | Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.